Abstract
Rosiglitazone is the second of the marketed thiazolidinediones to fall from grace, and its demise bears an uncanny resemblance to the earlier downfall of troglitazone. Both narratives demonstrate the inadequacy of a regulatory system that is mandated to place a higher value on commercial secrecy than on patient safety.
| Translated title of the contribution | Therapy: The second time as farce: rosiglitazone and the regulators |
|---|---|
| Original language | English |
| Pages (from-to) | 5 - 6 |
| Number of pages | 2 |
| Journal | Nature Reviews Endocrinology |
| Volume | 7(1) |
| DOIs | |
| Publication status | Published - Jan 2011 |